123 related articles for article (PubMed ID: 17408613)
1. Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats.
Voigt JP; Bramlage P; Fink H
Eur J Pharmacol; 2007 Jun; 564(1-3):131-7. PubMed ID: 17408613
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens; 2001 Mar; 19(3):465-73. PubMed ID: 11288817
[TBL] [Abstract][Full Text] [Related]
3. Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
Carraway JW; Park S; McCune SA; Holycross BJ; Radin MJ
J Cardiovasc Pharmacol; 1999 Mar; 33(3):451-60. PubMed ID: 10069682
[TBL] [Abstract][Full Text] [Related]
4. Sympatho-inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
Fundam Clin Pharmacol; 2003 Feb; 17(1):83-91. PubMed ID: 12588634
[TBL] [Abstract][Full Text] [Related]
5. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
van Esch JH; Moltzer E; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
[TBL] [Abstract][Full Text] [Related]
6. Control of hypertension with captopril affords better renal protection as compared with irbesartan in salt-loaded uremic rats.
Weissgarten J; Berman S; Efrati S; Rapoport M; Modai D; Cohn M; Aladjem M; Galperin E; Averbukh Z
Nephron Physiol; 2005; 101(1):p14-20. PubMed ID: 15925907
[TBL] [Abstract][Full Text] [Related]
7. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
Pu Q; Larouche I; Schiffrin EL
Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
[TBL] [Abstract][Full Text] [Related]
8. Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation.
Ager EI; Wen SW; Chan J; Chong WW; Neo JH; Christophi C
BMC Cancer; 2011 Jun; 11():274. PubMed ID: 21703011
[TBL] [Abstract][Full Text] [Related]
9. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine and cardiovascular effects of serotonin: selective role of brain angiotensin on vasopressin.
Saydoff JA; Rittenhouse PA; Carnes M; Armstrong J; Van De Kar LD; Brownfield MS
Am J Physiol; 1996 Mar; 270(3 Pt 1):E513-21. PubMed ID: 8638700
[TBL] [Abstract][Full Text] [Related]
11. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
Culman J; von Heyer C; Piepenburg B; Rascher W; Unger T
Eur J Pharmacol; 1999 Feb; 367(2-3):255-65. PubMed ID: 10079000
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis.
Hope S; Brecher P; Chobanian AV
Am J Hypertens; 1999 Jan; 12(1 Pt 1):28-34. PubMed ID: 10075381
[TBL] [Abstract][Full Text] [Related]
13. Protective Effect of Irbesartan an Angiotensin (AT1) Receptor Antagonist in Unpredictable Chronic Mild Stress Induced Depression in Mice.
Ayyub M; Najmi AK; Akhtar M
Drug Res (Stuttg); 2017 Jan; 67(1):59-64. PubMed ID: 27756096
[No Abstract] [Full Text] [Related]
14. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade.
Leenen FH; Yuan B
Hypertension; 2001 Mar; 37(3):981-4. PubMed ID: 11244027
[TBL] [Abstract][Full Text] [Related]
15. The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo.
Fukuhara M; Neves LA; Li P; Diz DI; Ferrario CM; Brosnihan KB
J Hypertens; 2001 Mar; 19(3 Pt 2):561-6. PubMed ID: 11327630
[TBL] [Abstract][Full Text] [Related]
16. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
J Cardiovasc Pharmacol; 2001 Jul; 38(1):141-8. PubMed ID: 11444497
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia.
Ortlepp JR; Breuer J; Eitner F; Kluge K; Kluge R; Floege J; Hollweg G; Hanrath P; Joost HG
Eur J Pharmacol; 2002 Feb; 436(1-2):145-50. PubMed ID: 11834258
[TBL] [Abstract][Full Text] [Related]
18. [Effects of combination therapy with angiotensin I-converting enzyme inhibitor and angiotensin 1 receptor antagonist on ventricular remodeling and expression of endothelial nitric oxide synthase].
Zhang RY; Huang YL; Sun YH
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(15):1053-6. PubMed ID: 16029550
[TBL] [Abstract][Full Text] [Related]
19. Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2⁻/⁻ mice.
Bridle KR; Sobbe AL; de Guzman CE; Santrampurwala N; Jaskowski LA; Clouston AD; Campbell CM; Nathan Subramaniam V; Crawford DH
Liver Int; 2015 Apr; 35(4):1451-63. PubMed ID: 24517519
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
